Table 1.
Summary of the Clinicopathological Features of the Patients, Status of the Molecules Studied, Tumor Kinetic Parameters, and Ploidy Status of the Tumors
| Histology* |
ADCs: |
32 |
SCCs: |
34 |
UL: |
9 |
| Lymph node invasion* | Yes: | 45 | no: | 30 | ||
| Tumor stage* | I: | 30 | II: | 27 | III: | 18 |
| Survival status† | Deceased (Md): | 26 (14) | Alive (Md): | 39 (18) | ||
| hCdt1 status* | NE: | 41 | OE: | 31 | ||
| hCdc6 status* | NE: | 37 | OE: | 38 | ||
| hGeminin status* | UE: | 8 | NE: | 35 | OE: | 25 |
| E2F-1 index (%) (EI) | M (n): | 39.8% (68) | SD: | 14.2% | Range: | 12–74% |
| p53 status*‡ | P: | 42 | N: | 31 | ||
| Proliferation index (%) (PI) | M (n): | 32.7% (67) | SD: | 12.5% | Range: | 5–70% |
| Apoptotic index (%) (AI) | Md (n): | 1.65% (64) | Range: | 0.1–10.6% | ||
| Growth index (GI = PI/AI) | Md (n): | 22.5% (64) | Range: | 4.0–290.0 | ||
| Ploidy status* | A: | 40 | D: | 30 |
*
Number of cases.
†
Follow-up up to 5-years; in months after surgery.
‡
p53 immunopositivity is associated with p53 mutations (P = 0.004, 17 of 23 versus 11 of 35).
P, positive; N, negative; A, D, aneuploid and diploid cases, respectively; ADC, adenocarcinoma; SCC, squamous cell carcinoma; UL, undifferentiated large carcinoma; Md, median value; NE, normal expression; OE, overexpression; UE, underexpression; M, mean value; SD, standard deviation; n, number of informative samples.